Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:pyrrolopyrimidine
go back to main search page
Accession:CHEBI:38670 term browser browse the term
Synonyms:related_synonym: pyrrolopyrimidines


show annotations for term's descendants           Sort by:
5-iodotubercidin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases phosphorylation EXP 5-iodotubercidin results in decreased phosphorylation of CDKN1B protein CTD PMID:26953159 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Clk1 CDC-like kinase 1 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK1 protein CTD PMID:26953159 NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000 		JBrowse link
G Clk2 CDC-like kinase 2 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK2 protein CTD PMID:26953159 NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985 		JBrowse link
G Clk3 CDC-like kinase 3 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK3 protein CTD PMID:26953159 NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181 		JBrowse link
G Clk4 CDC-like kinase 4 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK4 protein CTD PMID:26953159 NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352 		JBrowse link
G Dyrk1a dual specificity tyrosine phosphorylation regulated kinase 1A decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK1A protein CTD PMID:26953159 NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420 		JBrowse link
G Dyrk1b dual specificity tyrosine phosphorylation regulated kinase 1B decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK1B protein CTD PMID:26953159 NCBI chr 1:83,479,168...83,497,011
Ensembl chr 1:83,479,147...83,487,169 		JBrowse link
G Dyrk2 dual specificity tyrosine phosphorylation regulated kinase 2 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK2 protein CTD PMID:26953159 NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106 		JBrowse link
G Dyrk3 dual specificity tyrosine phosphorylation regulated kinase 3 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK3 protein CTD PMID:26953159 NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778 		JBrowse link
G Dyrk4 dual specificity tyrosine phosphorylation regulated kinase 4 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK4 protein CTD PMID:26953159 NCBI chr 4:159,715,658...159,757,660
Ensembl chr 4:159,715,417...159,757,627 		JBrowse link
G Ins2 insulin 2 increases secretion
affects secretion		 ISO 5-iodotubercidin results in increased secretion of INS protein
5-iodotubercidin affects the secretion of INS protein		 CTD PMID:26953159 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO 5-iodotubercidin results in increased expression of MMP3 mRNA CTD PMID:26953159 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961 		JBrowse link
G Nefm neurofilament medium chain increases expression ISO 5-iodotubercidin results in increased expression of NEFM mRNA CTD PMID:26953159 NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755 		JBrowse link
G Olfm4 olfactomedin 4 decreases expression ISO 5-iodotubercidin results in decreased expression of OLFM4 mRNA CTD PMID:26953159 NCBI chr15:55,385,100...55,429,687
Ensembl chr15:55,407,148...55,429,681 		JBrowse link
G Reg3b regenerating family member 3 beta decreases expression ISO 5-iodotubercidin results in decreased expression of REG3A mRNA CTD PMID:26953159 NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015 		JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO 5-iodotubercidin results in increased expression of SLC2A2 mRNA CTD PMID:26953159 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933 		JBrowse link
antalarmin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crhr1 corticotropin releasing hormone receptor 1 multiple interactions ISO antalarmin binds to and results in decreased activity of CRHR1 protein CTD PMID:16014403 NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression ISO antalarmin results in decreased expression of CYP11A1 mRNA CTD PMID:16014403 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression ISO antalarmin results in decreased expression of CYP17A1 mRNA CTD PMID:16014403 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573 		JBrowse link
G Faah fatty acid amide hydrolase multiple interactions EXP antalarmin inhibits the reaction [Corticosterone results in increased activity of FAAH protein] CTD PMID:26821211 NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677 		JBrowse link
G Star steroidogenic acute regulatory protein decreases expression ISO antalarmin results in decreased expression of STAR mRNA CTD PMID:16014403 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression ISO antalarmin results in decreased expression of SULT2A1 mRNA CTD PMID:16014403 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
baricitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aak1 AP2 associated kinase 1 decreases activity ISO baricitinib results in decreased activity of AAK1 protein CTD PMID:32113509 NCBI chr 4:119,300,128...119,451,834
Ensembl chr 4:119,295,257...119,450,969 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO baricitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA] CTD PMID:23968543 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Gak cyclin G associated kinase decreases activity ISO baricitinib results in decreased activity of GAK protein CTD PMID:32113509 NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398 		JBrowse link
G Id2 inhibitor of DNA binding 2 multiple interactions ISO baricitinib inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of ID2 protein] CTD PMID:32428222 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400 		JBrowse link
G Jak1 Janus kinase 1 decreases activity
multiple interactions		 ISO baricitinib results in decreased activity of JAK1 protein
baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]		 CTD PMID:23968543 PMID:29687421 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jak2 Janus kinase 2 decreases activity
multiple interactions		 ISO baricitinib results in decreased activity of JAK2 protein
baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]		 CTD PMID:23968543 PMID:29687421 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein] CTD PMID:23968543 NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536 		JBrowse link
G Osm oncostatin M multiple interactions ISO baricitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein] CTD PMID:23968543 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO baricitinib inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased phosphorylation of STAT1 protein] CTD PMID:32428222 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
capivasertib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO capivasertib results in increased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation ISO capivasertib results in decreased phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:26853465 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein; CA 074 methyl ester inhibits the reaction [[capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein] CTD PMID:26853465 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases expression		 ISO bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form] CTD PMID:26853465 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Rpl18 ribosomal protein L18 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 protein] CTD PMID:37061066 NCBI chr 1:96,188,811...96,191,452
Ensembl chr 1:96,188,112...96,191,452 		JBrowse link
G Rps21-ps1 ribosomal protein S21, pseudogene 1 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 protein] CTD PMID:37061066 NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO capivasertib results in decreased phosphorylation of RPS6 protein CTD PMID:26853465 PMID:32397857 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Sqstm1 sequestosome 1 affects expression ISO capivasertib affects the expression of SQSTM1 protein CTD PMID:26853465 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO capivasertib results in decreased expression of SREBF1 protein CTD PMID:26853465 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 protein] CTD PMID:37061066 NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807 		JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf4 activating transcription factor 4 multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] CTD PMID:30602124 PMID:32578922 PMID:36030031 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 protein] CTD PMID:36030031 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
decreases activity		 EXP GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]]
GSK2656157 results in decreased activity of EIF2AK3 protein		 CTD PMID:35028790 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO
EXP		 GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]
GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]		 CTD PMID:30602124 PMID:32357311 PMID:35028790 PMID:36030031 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO GSK2656157 inhibits the reaction [Palmitic Acid results in decreased expression of FOXO1 mRNA] CTD PMID:36030031 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790 		JBrowse link
G Ostn osteocrin multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA] CTD PMID:30602124 NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] CTD PMID:32357311 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
pemetrexed term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc5 ATP binding cassette subfamily C member 5 decreases response to substance ISO ABCC5 protein results in decreased susceptibility to Pemetrexed CTD PMID:15897250 NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253 		JBrowse link
G Alk ALK receptor tyrosine kinase affects response to substance ISO ALK gene mutant form affects the susceptibility to Pemetrexed CTD PMID:21336183 NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034 		JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression
multiple interactions		 ISO Pemetrexed results in increased expression of BBC3 protein
xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein]		 CTD PMID:35259468 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein CTD PMID:19351772 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein CTD PMID:19351772 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G C3 complement C3 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein CTD PMID:22975265 NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA CTD PMID:22975265 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein CTD PMID:19351772 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein CTD PMID:19351772 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases response to substance ISO CFLAR results in decreased susceptibility to Pemetrexed CTD PMID:21726997 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] CTD PMID:21726997 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dhfr dihydrofolate reductase multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA CTD PMID:22975265 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression		 ISO Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]
Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein		 CTD PMID:23912706 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963 		JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions		 ISO Pemetrexed results in increased expression of FAS protein
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]		 CTD PMID:15161716 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fpgs folylpolyglutamate synthase increases response to substance ISO FPGS protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563 		JBrowse link
G Ggh gamma-glutamyl hydrolase affects response to substance ISO GGH protein affects the susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA CTD PMID:22975265 NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175 		JBrowse link
G Il11 interleukin 11 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA CTD PMID:22975265 NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129 		JBrowse link
G Il13ra2 interleukin 13 receptor subunit alpha 2 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA CTD PMID:22975265 NCBI chr  X:111,002,590...111,074,053
Ensembl chr  X:111,002,592...111,072,381 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA CTD PMID:22975265 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA CTD PMID:22975265 NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256 		JBrowse link
G Il33 interleukin 33 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA CTD PMID:22975265 NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373 		JBrowse link
G Il7r interleukin 7 receptor multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA CTD PMID:22975265 NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757 		JBrowse link
G Klrc1 killer cell lectin like receptor C1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA CTD PMID:22975265 NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases expression
increases response to substance		 ISO Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein
KRAS gene mutant form results in increased susceptibility to Pemetrexed		 CTD PMID:24688052 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase increases response to substance ISO MTHFD2 protein results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608 		JBrowse link
G Npm1 nucleophosmin 1 decreases response to substance ISO NPM1 protein results in decreased susceptibility to Pemetrexed CTD PMID:24736981 NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645 		JBrowse link
G Nras NRAS proto-oncogene, GTPase increases response to substance ISO NRAS gene mutant form results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626 		JBrowse link
G Rbm17 RNA binding motif protein 17 decreases response to substance ISO RBM17 protein results in decreased susceptibility to Pemetrexed CTD PMID:16061639 NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014 		JBrowse link
G Slc19a1 solute carrier family 19 member 1 multiple interactions
increases response to substance		 ISO Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate]
SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed		 CTD PMID:16505119 PMID:21879757 NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972 		JBrowse link
G Slc46a1 solute carrier family 46 member 1 multiple interactions
increases activity
increases response to substance		 ISO Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate]
Pemetrexed results in increased activity of SLC46A1 protein
SLC46A1 protein results in increased susceptibility to Pemetrexed		 CTD PMID:21879757 NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA CTD PMID:22975265 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA CTD PMID:22975265 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects response to substance		 ISO TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]
TP53 protein affects the susceptibility to Pemetrexed		 CTD PMID:15161716 PMID:17339891 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Traf1 TNF receptor-associated factor 1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA CTD PMID:22975265 NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807 		JBrowse link
G Tymp thymidine phosphorylase increases response to substance ISO TYMP protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874 		JBrowse link
G Tyms thymidylate synthetase decreases activity
multiple interactions
affects response to substance		 ISO Pemetrexed results in decreased activity of TYMS protein
TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed		 CTD PMID:15161716 PMID:17339891 PMID:21742432 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
pevonedistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bbc3 Bcl-2 binding component 3 affects expression ISO pevonedistat affects the expression of BBC3 mRNA CTD PMID:24634471 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression ISO pevonedistat affects the expression of BCL2 mRNA CTD PMID:24634471 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 affects expression ISO pevonedistat affects the expression of BCL2L1 mRNA CTD PMID:24634471 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 affects expression ISO pevonedistat affects the expression of BCL2L11 mRNA; pevonedistat affects the expression of BCL2L11 protein CTD PMID:24634471 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; pevonedistat inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22110742 PMID:34476871 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccl17 C-C motif chemokine ligand 17 affects expression ISO pevonedistat affects the expression of CCL17 mRNA CTD PMID:24634471 NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819 		JBrowse link
G Ccl22 C-C motif chemokine ligand 22 affects expression ISO pevonedistat affects the expression of CCL22 mRNA CTD PMID:24634471 NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 affects expression ISO pevonedistat affects the expression of CCL5 mRNA CTD PMID:24634471 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccnd1 cyclin D1 affects expression ISO pevonedistat affects the expression of CCND1 mRNA CTD PMID:24634471 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd2 cyclin D2 affects expression ISO pevonedistat affects the expression of CCND2 mRNA CTD PMID:24634471 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495 		JBrowse link
G Cd40 CD40 molecule affects expression ISO pevonedistat affects the expression of CD40 mRNA CTD PMID:24634471 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534 		JBrowse link
G Cd74 CD74 molecule affects expression ISO pevonedistat affects the expression of CD74 mRNA CTD PMID:24634471 NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003 		JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases abundance ISO pevonedistat results in increased abundance of CDT1 protein CTD PMID:22110742 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO pevonedistat affects the expression of CFLAR mRNA CTD PMID:24634471 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Ctnnb1 catenin beta 1 increases abundance
multiple interactions		 ISO pevonedistat results in increased abundance of CTNNB1 protein
pevonedistat inhibits the reaction [Cisplatin results in decreased expression of CTNNB1 mRNA]		 CTD PMID:22110742 PMID:34476871 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cul1 cullin 1 decreases metabolic processing ISO pevonedistat results in decreased metabolism of CUL1 protein CTD PMID:22110742 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980 		JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 affects expression ISO pevonedistat affects the expression of CXCL9 mRNA CTD PMID:24634471 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435 		JBrowse link
G Cxcr3 C-X-C motif chemokine receptor 3 affects expression ISO pevonedistat affects the expression of CXCR3 mRNA CTD PMID:24634471 NCBI chr  X:66,844,318...66,846,969
Ensembl chr  X:66,844,318...66,846,969 		JBrowse link
G Cxcr5 C-X-C motif chemokine receptor 5 affects expression ISO pevonedistat affects the expression of CXCR5 mRNA CTD PMID:24634471 NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893 		JBrowse link
G Epas1 endothelial PAS domain protein 1 multiple interactions ISO [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein CTD PMID:35504338 NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta affects expression ISO pevonedistat affects the expression of GADD45B mRNA CTD PMID:24634471 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein CTD PMID:35504338 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hsf1 heat shock transcription factor 1 increases activity ISO pevonedistat results in increased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in increased expression of IL1B protein] CTD PMID:34476871 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in increased expression of IL6 protein] CTD PMID:34476871 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases abundance
multiple interactions		 ISO pevonedistat results in increased abundance of JUN protein
Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]		 CTD PMID:22110742 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III increases expression ISO pevonedistat results in increased expression of MAF1 protein CTD PMID:31645432 NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249 		JBrowse link
G Mir155hg Mir155 host gene affects expression ISO pevonedistat affects the expression of MIR155HG mRNA CTD PMID:24634471 NCBI chr11:23,773,468...23,775,697 JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO pevonedistat results in increased expression of MYC protein CTD PMID:25897075 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA] CTD PMID:34476871 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 affects activity ISO pevonedistat affects the activity of NFKB1 protein CTD PMID:24634471 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation ISO pevonedistat results in increased phosphorylation of NFKBIA protein CTD PMID:22110742 PMID:24634471 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions		 ISO pevonedistat results in increased cleavage of PARP1 protein
pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]		 CTD PMID:22110742 PMID:24634471 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases abundance
affects expression
multiple interactions		 ISO pevonedistat results in increased abundance of PMAIP1 protein
pevonedistat affects the expression of PMAIP1 mRNA
Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]		 CTD PMID:22110742 PMID:24634471 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects activity ISO pevonedistat affects the activity of RELA protein CTD PMID:24634471 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 increases expression ISO pevonedistat results in increased expression of RICTOR protein CTD PMID:25897075 NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426 		JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 increases expression ISO pevonedistat results in increased expression of RPTOR protein CTD PMID:25897075 NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983 		JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A affects expression ISO pevonedistat affects the expression of STAT5A mRNA CTD PMID:24634471 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in increased expression of TNF protein] CTD PMID:34476871 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO pevonedistat inhibits the reaction [Cisplatin results in decreased expression of TNFAIP3 mRNA] CTD PMID:34476871 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282 		JBrowse link
G Uba3 ubiquitin-like modifier activating enzyme 3 decreases activity ISO pevonedistat results in decreased activity of UBA3 protein CTD PMID:22110742 NCBI chr 4:129,789,526...129,810,707
Ensembl chr 4:129,789,204...129,810,606 		JBrowse link
G Wee1 WEE1 G2 checkpoint kinase increases abundance ISO pevonedistat results in increased abundance of WEE1 protein CTD PMID:22110742 NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688 		JBrowse link
PF-956980 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA] CTD PMID:23968543 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein] CTD PMID:23968543 NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536 		JBrowse link
G Osm oncostatin M multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
ruxolitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA CTD PMID:30012499 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased phosphorylation of ATM protein CTD PMID:30012499 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]
[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of BAX mRNA		 CTD PMID:24973641 PMID:30012499 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA CTD PMID:30012499 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA CTD PMID:30012499 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA CTD PMID:30012499 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Cat catalase multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CAT mRNA CTD PMID:30012499 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CCND1 mRNA CTD PMID:30012499 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO ruxolitinib inhibits the reaction [DDT results in decreased expression of CDH1 mRNA] CTD PMID:24820114 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO ruxolitinib inhibits the reaction [DDT results in increased expression of CDH2 mRNA] CTD PMID:24820114 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CDK2 mRNA CTD PMID:30012499 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased phosphorylation of CHEK2 protein CTD PMID:30012499 NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
decreases expression		 ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]
ruxolitinib results in decreased expression of CXCL10 mRNA		 CTD PMID:22941906 PMID:28365849 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 multiple interactions
decreases expression		 ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]
ruxolitinib results in decreased expression of CXCL11 mRNA		 CTD PMID:22941906 PMID:28365849 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Edn1 endothelin 1 decreases phosphorylation EXP ruxolitinib results in decreased phosphorylation of EDN1 protein CTD PMID:30670587 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] CTD PMID:24973641 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of GSR mRNA CTD PMID:30012499 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [Arsenic Trioxide co-treated with ruxolitinib] results in increased phosphorylation of H2AX protein CTD PMID:30012499 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G Ifna1 interferon, alpha 1 multiple interactions ISO ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925 		JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF1 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF9 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of SP100 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT1 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT2 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of TLR3 mRNA] CTD PMID:28365849 NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523 		JBrowse link
G Ifng interferon gamma multiple interactions ISO ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of IL10 protein] CTD PMID:24973641 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il13 interleukin 13 multiple interactions ISO ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL13 protein] CTD PMID:32725971 NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein] CTD PMID:24973641 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of IL1B protein]
ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL1B protein]		 CTD PMID:24973641 PMID:32725971 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL5 protein] CTD PMID:32725971 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213 		JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF1 mRNA] CTD PMID:28365849 NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166 		JBrowse link
G Irf7 interferon regulatory factor 7 decreases expression ISO ruxolitinib results in decreased expression of IRF7 mRNA CTD PMID:22941906 NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832 		JBrowse link
G Irf9 interferon regulatory factor 9 multiple interactions ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF9 mRNA] CTD PMID:28365849 NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO ruxolitinib inhibits the reaction [DDT results in increased expression of ITGB1 mRNA] CTD PMID:24820114 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Jak1 Janus kinase 1 multiple interactions
decreases activity		 ISO ruxolitinib inhibits the reaction [DDT results in increased phosphorylation of JAK1 protein]
ruxolitinib results in decreased activity of JAK1 protein		 CTD PMID:24820114 PMID:24883332 PMID:26300391 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jak2 Janus kinase 2 affects response to substance
multiple interactions
decreases activity		 ISO JAK2 gene mutant form affects the susceptibility to ruxolitinib
[ruxolitinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of JAK2 protein
ruxolitinib results in decreased activity of JAK2 protein		 CTD PMID:24883332 PMID:26300391 PMID:30012499 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO ruxolitinib promotes the reaction [TNF protein affects the localization of JUN protein] CTD PMID:22941906 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] CTD PMID:24973641 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of MYC mRNA CTD PMID:30012499 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO ruxolitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein] CTD PMID:22941906 NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028 		JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 multiple interactions ISO ruxolitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein] CTD PMID:22941906 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213 		JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of NOX1 mRNA CTD PMID:30012499 NCBI chr  X:97,279,058...97,332,291
Ensembl chr  X:97,279,056...97,302,236 		JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of RAC1 mRNA CTD PMID:30012499 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of and affects the localization of RELA protein] CTD PMID:24973641 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Relb RELB proto-oncogene, NF-kB subunit multiple interactions ISO ruxolitinib inhibits the reaction [TNF protein affects the localization of RELB protein] CTD PMID:22941906 NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of SOD1 mRNA CTD PMID:30012499 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sp100 SP100 nuclear antigen multiple interactions ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of SP100 mRNA] CTD PMID:28365849 NCBI chr 9:86,310,990...86,377,036
Ensembl chr 9:86,311,032...86,377,034 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 decreases expression
decreases phosphorylation
multiple interactions		 ISO ruxolitinib results in decreased expression of STAT1 mRNA
ruxolitinib results in decreased phosphorylation of STAT1 protein
ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT1 mRNA]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]		 CTD PMID:22941906 PMID:28365849 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Stat2 signal transducer and activator of transcription 2 multiple interactions ISO ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT2 mRNA]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 PMID:28365849 NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of STAT3 protein; ruxolitinib inhibits the reaction [DDT results in increased phosphorylation of STAT3 protein] CTD PMID:24820114 PMID:30012499 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases phosphorylation ISO ruxolitinib results in decreased phosphorylation of STAT5B protein
ruxolitinib results in decreased phosphorylation of STAT5B protein; ruxolitinib results in decreased phosphorylation of STAT5B protein mutant form		 CTD PMID:29200404 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of TLR3 mRNA] CTD PMID:28365849 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO ruxolitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; ruxolitinib promotes the reaction [TNF protein affects the localization of JUN protein]; ruxolitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased secretion of TNF protein]		 CTD PMID:22941906 PMID:24973641 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of TP53 mRNA; [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of TP53 protein CTD PMID:30012499 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions ISO [ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of TXNRD1 mRNA CTD PMID:30012499 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression ISO ruxolitinib results in increased expression of UCP1 mRNA CTD PMID:25487280 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO ruxolitinib results in increased expression of VEGFA mRNA CTD PMID:26300391 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
tofacitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA] CTD PMID:21383241 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases metabolic processing ISO AKR1C1 protein results in increased metabolism of tofacitinib metabolite CTD PMID:27117606 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:21383241 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ampd2 adenosine monophosphate deaminase 2 multiple interactions
decreases expression		 ISO [tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine CTD PMID:25496463 NCBI chr 2:195,707,609...195,720,454
Ensembl chr 2:195,707,610...195,720,271 		JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression ISO tofacitinib results in decreased expression of BST2 mRNA CTD PMID:25487280 NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions		 ISO tofacitinib results in decreased expression of CCL2 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]		 CTD PMID:22121136 PMID:23968543 PMID:25398374 PMID:36416909 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] CTD PMID:36416909 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein] CTD PMID:22121136 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccnd1 cyclin D1 increases expression ISO tofacitinib results in increased expression of CCND1 mRNA CTD PMID:26300391 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ctsk cathepsin K decreases expression ISO tofacitinib results in decreased expression of CTSK protein CTD PMID:21937456 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases expression
multiple interactions
decreases secretion		 ISO
EXP		 tofacitinib results in decreased expression of CXCL10 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]
tofacitinib results in decreased secretion of CXCL10 protein		 CTD PMID:22121136 PMID:22899318 PMID:22941906 PMID:24213371 PMID:25398374 More... NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 decreases expression
multiple interactions		 ISO tofacitinib results in decreased expression of CXCL11 mRNA
tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]		 CTD PMID:22941906 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression ISO tofacitinib results in decreased expression of CXCL13 mRNA CTD PMID:25398374 NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933 		JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions
decreases expression		 ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]
tofacitinib results in decreased expression of CXCL9 mRNA		 CTD PMID:22941906 PMID:24213371 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 increases metabolic processing ISO CYP2C19 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing ISO CYP2D6 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
increases oxidation		 ISO CYP3A4 protein results in increased metabolism of tofacitinib
CYP3A4 protein results in increased oxidation of tofacitinib metabolite		 CTD PMID:27117606 PMID:31414593 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Gli1 GLI family zinc finger 1 increases expression ISO tofacitinib results in increased expression of GLI1 mRNA CTD PMID:25487280 NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 decreases expression ISO tofacitinib results in decreased expression of IFI27 mRNA CTD PMID:25487280 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Ifi35 interferon-induced protein 35 decreases expression ISO tofacitinib results in decreased expression of IFI35 mRNA CTD PMID:25487280 NCBI chr10:86,381,023...86,389,279
Ensembl chr10:86,381,010...86,389,952 		JBrowse link
G Ifi44 interferon-induced protein 44 decreases expression ISO tofacitinib results in decreased expression of IFI44 mRNA CTD PMID:25487280 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844 		JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 decreases expression ISO tofacitinib results in decreased expression of IFIT3 mRNA CTD PMID:25487280 NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO tofacitinib results in decreased expression of IFITM1 mRNA CTD PMID:25487280 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169 		JBrowse link
G Ifna1 interferon, alpha 1 multiple interactions ISO tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925 		JBrowse link
G Ifng interferon gamma multiple interactions ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IFNG protein]
tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of CXCL8 protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]		 CTD PMID:21383241 PMID:22941906 PMID:24213371 PMID:33130239 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein] CTD PMID:21383241 PMID:24285838 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] CTD PMID:36416909 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
G Il15 interleukin 15 multiple interactions ISO tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605 NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO tofacitinib inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of and results in increased secretion of IL17A protein] CTD PMID:26738536 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression		 ISO
EXP		 tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]
tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]
tofacitinib results in decreased expression of IL1B mRNA		 CTD PMID:21383241 PMID:21937456 PMID:22899318 PMID:22941906 PMID:33130239 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605 PMID:21383241 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566 		JBrowse link
G Il21 interleukin 21 multiple interactions ISO tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]		 CTD PMID:21383241 NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996 		JBrowse link
G Il23a interleukin 23 subunit alpha multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein] CTD PMID:21383241 PMID:21937456 NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923 		JBrowse link
G Il23r interleukin 23 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA] CTD PMID:21383241 NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions		 ISO
EXP		 tofacitinib results in decreased expression of IL6 mRNA
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]
tofacitinib results in decreased expression of and results in decreased secretion of IL6 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA]		 CTD PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6r interleukin 6 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein] CTD PMID:21548952 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536 		JBrowse link
G Irf7 interferon regulatory factor 7 decreases expression ISO tofacitinib results in decreased expression of IRF7 mRNA CTD PMID:22941906 PMID:25487280 NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832 		JBrowse link
G Irf9 interferon regulatory factor 9 decreases expression ISO tofacitinib results in decreased expression of IRF9 mRNA CTD PMID:25487280 NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236 		JBrowse link
G Isg15 ISG15 ubiquitin-like modifier decreases expression ISO tofacitinib results in decreased expression of ISG15 mRNA CTD PMID:25487280 NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435 		JBrowse link
G Jak1 Janus kinase 1 decreases activity
multiple interactions		 ISO tofacitinib results in decreased activity of JAK1 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]		 CTD PMID:21548952 PMID:23968543 PMID:24883332 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jak2 Janus kinase 2 affects response to substance
multiple interactions
decreases activity		 ISO JAK2 gene mutant form affects the susceptibility to tofacitinib
tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]
tofacitinib results in decreased activity of JAK2 protein		 CTD PMID:21548952 PMID:21844139 PMID:23968543 PMID:26300391 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Jak3 Janus kinase 3 decreases activity
multiple interactions		 ISO tofacitinib results in decreased activity of JAK3 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]		 CTD PMID:21548952 PMID:23689514 PMID:23968543 PMID:24883332 PMID:26300391 More... NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein] CTD PMID:22941906 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Klhl31 kelch-like family member 31 increases expression ISO tofacitinib results in increased expression of KLHL31 mRNA CTD PMID:25487280 NCBI chr 8:78,515,514...78,538,873
Ensembl chr 8:78,515,514...78,538,873 		JBrowse link
G Krt16 keratin 16 decreases expression ISO tofacitinib results in decreased expression of KRT16 mRNA CTD PMID:27059729 NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA] CTD PMID:27708194 NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein] CTD PMID:21548952 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein] CTD PMID:21548952 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein] CTD PMID:21548952 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein] CTD PMID:21548952 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases expression ISO tofacitinib results in decreased expression of MMP1 mRNA CTD PMID:25398374 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097 		JBrowse link
G Mmp3 matrix metallopeptidase 3 decreases expression ISO tofacitinib results in decreased expression of MMP3 mRNA CTD PMID:25398374 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA] CTD PMID:24285838 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO tofacitinib results in increased expression of COX1 protein CTD PMID:25487280 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Mx1 MX dynamin like GTPase 1 decreases expression ISO tofacitinib results in decreased expression of MX1 mRNA CTD PMID:25487280 NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507 		JBrowse link
G Mx2 MX dynamin like GTPase 2 decreases expression ISO tofacitinib results in decreased expression of MX2 mRNA CTD PMID:25487280 NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein] CTD PMID:22941906 NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028 		JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein] CTD PMID:22941906 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213 		JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A decreases expression ISO tofacitinib results in decreased expression of OAS1 mRNA CTD PMID:25487280 NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517 		JBrowse link
G Oas2 2'-5' oligoadenylate synthetase 2 decreases expression ISO tofacitinib results in decreased expression of OAS2 mRNA CTD PMID:25487280 NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371 		JBrowse link
G Osm oncostatin M multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]
tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of S100A7 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]		 CTD PMID:21548952 PMID:21937456 PMID:23968543 PMID:25252914 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313 		JBrowse link
G Prdm16 PR/SET domain 16 increases expression ISO tofacitinib results in increased expression of PRDM16 protein CTD PMID:25487280 NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601 		JBrowse link
G Prl prolactin multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein] CTD PMID:27708194 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062 		JBrowse link
G Relb RELB proto-oncogene, NF-kB subunit multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein] CTD PMID:22941906 NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507 		JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907 		JBrowse link
G Rsad2 radical S-adenosyl methionine domain containing 2 decreases expression ISO tofacitinib results in decreased expression of RSAD2 mRNA CTD PMID:25487280 NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699 		JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A increases expression ISO tofacitinib results in increased expression of SDHA protein CTD PMID:25487280 NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535 		JBrowse link
G Sele selectin E decreases expression EXP tofacitinib results in decreased expression of SELE mRNA CTD PMID:22899318 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Selp selectin P decreases expression EXP tofacitinib results in decreased expression of SELP mRNA CTD PMID:22899318 NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845 		JBrowse link
G Sfrp5 secreted frizzled-related protein 5 increases expression ISO tofacitinib results in increased expression of SFRP5 mRNA CTD PMID:25487280 NCBI chr 1:241,006,762...241,011,224
Ensembl chr 1:241,006,762...241,011,224 		JBrowse link
G Shh sonic hedgehog signaling molecule increases expression ISO tofacitinib results in increased expression of SHH mRNA CTD PMID:25487280 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO tofacitinib results in decreased expression of SOCS3 mRNA CTD PMID:25487280 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 decreases expression
multiple interactions
decreases phosphorylation		 ISO tofacitinib results in decreased expression of STAT1 mRNA; tofacitinib results in decreased expression of STAT1 protein modified form
tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
tofacitinib results in decreased phosphorylation of STAT1 protein		 CTD PMID:21383241 PMID:21548952 PMID:22121136 PMID:22941906 PMID:23968543 More... NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Stat2 signal transducer and activator of transcription 2 multiple interactions ISO tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases activity
multiple interactions
decreases expression
decreases phosphorylation		 ISO tofacitinib results in decreased activity of STAT3 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
tofacitinib results in decreased expression of STAT3 protein modified form
tofacitinib results in decreased phosphorylation of STAT3 protein		 CTD PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More... NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions		 ISO
EXP		 tofacitinib results in decreased phosphorylation of STAT5A protein
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]		 CTD PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases phosphorylation
multiple interactions		 ISO
EXP		 tofacitinib results in decreased phosphorylation of STAT5B protein; tofacitinib results in decreased phosphorylation of STAT5B protein mutant form
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein]		 CTD PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194 PMID:29200404 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]; tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein]; tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]		 CTD PMID:21383241 PMID:21937456 PMID:22121136 PMID:22941906 PMID:25487280 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 decreases expression ISO tofacitinib results in decreased expression of TNFSF10 mRNA CTD PMID:25487280 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions
decreases expression		 ISO
EXP		 tofacitinib results in decreased expression of and results in decreased secretion of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 mRNA
tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]		 CTD PMID:21937456 PMID:22899318 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression
multiple interactions		 ISO tofacitinib results in increased expression of UCP1 mRNA; tofacitinib results in increased expression of UCP1 protein
cyclopamine inhibits the reaction [tofacitinib results in increased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]		 CTD PMID:25487280 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852 		JBrowse link
G Usp18 ubiquitin specific peptidase 18 decreases expression ISO tofacitinib results in decreased expression of USP18 mRNA CTD PMID:25487280 NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO tofacitinib results in increased expression of VEGFA mRNA CTD PMID:26300391 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
toyocamycin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp1 caspase 1 multiple interactions ISO Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CASP1 protein] CTD PMID:37692514 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL1B protein] CTD PMID:37692514 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NLRP3 protein] CTD PMID:37692514 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions ISO Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of PINK1 protein] CTD PMID:37692514 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of XBP1 protein alternative form] CTD PMID:37692514 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19808
    chemical entity 19806
      atom 19806
        nonmetal atom 19744
          nitrogen atom 18933
            nitrogen molecular entity 18933
              organonitrogen compound 18783
                organonitrogen heterocyclic compound 18126
                  pyrrolopyrimidine 220
                    ((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid 0
                    (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate 0
                    (2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol 0
                    (2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol 0
                    (2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine 0
                    (2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid 0
                    (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 0
                    (3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol 0
                    (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol 0
                    (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol 0
                    (3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol 0
                    1,5-diazabicyclo[4.3.0]-non-5-ene 0
                    1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol 0
                    2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide 0
                    2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one 0
                    2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 0
                    2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 0
                    2-amino-4-methoxy-5-cyanopyrrolo[2,3-d]pyrimidine 0
                    3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium 0
                    3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                    3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                    3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile 0
                    3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium 0
                    5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 0
                    6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine + 0
                    7,8-Dihydro-3-methylpyrrolo[1,2-a]pyrimidin-2(6H)-one 0
                    7-Carboxy-7-carbaguanine 0
                    7-Deaza-2'-deoxyguanosine 0
                    7-aminomethyl-7-deazaguanine 0
                    7-carboxy-7-deazaguanine + 0
                    7-cyano-7-deazaguanine 0
                    7-formamidino-7-deazaguanine + 0
                    7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 0
                    9-deazahypoxanthine 0
                    GSK2656157 7
                    GWARJD14 0
                    LSM-16748 0
                    LSM-17257 0
                    LSM-18936 0
                    LSM-24201 0
                    LSM-32669 0
                    LSM-33192 0
                    N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine 0
                    N-glycosylpyrrolopyrimidine + 21
                    PF-956980 4
                    RK-24466 0
                    [(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate 0
                    antalarmin 6
                    baricitinib 9
                    batzelladine A 0
                    batzelladine B 0
                    capivasertib 11
                    delgocitinib 0
                    epoxyqueuine 0
                    immucillin G 0
                    immucillin H 0
                    mirodenafil 0
                    pemetrexed 37
                    pevonedistat 43
                    queuine + 0
                    ritlecitinib 0
                    ruxolitinib + 53
                    tofacitinib + 87
                    vibegron 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19808
    subatomic particle 19806
      composite particle 19806
        hadron 19806
          baryon 19806
            nucleon 19806
              atomic nucleus 19806
                atom 19806
                  main group element atom 19756
                    p-block element atom 19756
                      p-block molecular entity 19756
                        carbon group molecular entity 19705
                          organic molecular entity 19702
                            organic molecule 19655
                              organic cyclic compound 19468
                                organic heterocyclic compound 18848
                                  organic heteropolycyclic compound 18278
                                    organic heterobicyclic compound 17216
                                      pyrrolopyrimidine 220
                                        ((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid 0
                                        (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate 0
                                        (2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol 0
                                        (2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol 0
                                        (2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine 0
                                        (2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid 0
                                        (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 0
                                        (3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol 0
                                        (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol 0
                                        (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol 0
                                        (3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol 0
                                        1,5-diazabicyclo[4.3.0]-non-5-ene 0
                                        1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol 0
                                        2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide 0
                                        2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one 0
                                        2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 0
                                        2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 0
                                        2-amino-4-methoxy-5-cyanopyrrolo[2,3-d]pyrimidine 0
                                        3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium 0
                                        3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                                        3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                                        3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile 0
                                        3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium 0
                                        5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 0
                                        6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine + 0
                                        7,8-Dihydro-3-methylpyrrolo[1,2-a]pyrimidin-2(6H)-one 0
                                        7-Carboxy-7-carbaguanine 0
                                        7-Deaza-2'-deoxyguanosine 0
                                        7-aminomethyl-7-deazaguanine 0
                                        7-carboxy-7-deazaguanine + 0
                                        7-cyano-7-deazaguanine 0
                                        7-formamidino-7-deazaguanine + 0
                                        7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 0
                                        9-deazahypoxanthine 0
                                        GSK2656157 7
                                        GWARJD14 0
                                        LSM-16748 0
                                        LSM-17257 0
                                        LSM-18936 0
                                        LSM-24201 0
                                        LSM-32669 0
                                        LSM-33192 0
                                        N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine 0
                                        N-glycosylpyrrolopyrimidine + 21
                                        PF-956980 4
                                        RK-24466 0
                                        [(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate 0
                                        antalarmin 6
                                        baricitinib 9
                                        batzelladine A 0
                                        batzelladine B 0
                                        capivasertib 11
                                        delgocitinib 0
                                        epoxyqueuine 0
                                        immucillin G 0
                                        immucillin H 0
                                        mirodenafil 0
                                        pemetrexed 37
                                        pevonedistat 43
                                        queuine + 0
                                        ritlecitinib 0
                                        ruxolitinib + 53
                                        tofacitinib + 87
                                        vibegron 0
paths to the root